A Clinical Case of MOGAD

Background

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating inflammatory disease of the central nervous system (CNS). It is characterized by the presence of anti-MOG antibodies and a core clinical demyelinating event such as optic neuritis or transverse myelitis. The clinical spectrum of this disease includes optic neuritis, transverse myelitis encephalopathy, and seizures. Optic neuritis is the most frequent presentation at time of diagnosis. The disease can be relapsing/remitting [1]. It can start in all age groups, but the average age is 30 years old [2].

Publication History

Received: 29 October 2023

Accepted: 22 January 2024

Article published online:
23 April 2024

• References

• 1 Sechi E, Cacciaguerra L, Chen JJ. et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 2022; 13: 885218
• 2 Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated diseas: a review of prevalence and incidence worldwide. Front Neurol 2023; 14: 1260358
• 3 Gupta S, Sethi P, Duvesh RK. et al. Optic perineuritis. BMJ Open Ophthalmol 2021; 6: 745
• 4 Abel A, McClelland C, Lee MS. Critical review: Typical and atypical optic neuritis. Surv Ophthalmol 2019; 64: 770-779
• 5 Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis – UpToDate [Internet]. Accessed January 24, 2024 at: https://www.uptodate.com/contents/myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-clinical-features-and-diagnosis%23H774067702